SCHEMBL4190734

SCHEMBL4190734

O=C(Cc1cccc(OC(F)(F)F)c1)c1c(O)c2cccnc2n(-c2cccc(C(F)(F)F)c2)c1=O

nearest known ligand 0.44

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PPARG P37231 1/20 0.41
PDE4B Q07343 2/20 0.40
PDE4D Q08499 2/20 0.40
TP53 P04637 2/20 0.40
TRPV1 Q8NER1 1/20 0.40
POLB P06746 1/20 0.40
FEN1 P39748 1/20 0.39
MAPT P10636 1/20 0.39
KCNH2 Q12809 1/20 0.38
SCN5A Q14524 1/20 0.38
SCN9A Q15858 1/20 0.38
P2RY1 P47900 1/20 0.38
F2RL3 Q96RI0 1/20 0.37
CXCR3 P49682 1/20 0.37
NPY5R Q15761 1/20 0.37
ABCB1 P08183 1/20 0.37
ALDH1A1 P00352 1/20 0.37
KCNN4 O15554 1/20 0.37
HSD17B13 Q7Z5P4 1/20 0.37
IDO1 P14902 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4187633 0.97 PPARG (0.41) PPARGPDE4BPDE4DTP53TRPV1
SCHEMBL4185730 0.95 PDE4B (0.43) PDE4BPDE4DFEN1KCNH2SCN5A
SCHEMBL4189465 0.92 BCL2L1 (0.42) PPARGPDE4BPDE4DTP53TRPV1
SCHEMBL4187079 0.92 PDE4B (0.41) PPARGPDE4BPDE4DTP53POLB
SCHEMBL4183574 0.91 TP53 (0.44) PPARGPDE4BPDE4DTP53TRPV1
SCHEMBL4187682 0.91 PDE4B (0.43) PPARGPDE4BPDE4DFEN1MAPT
SCHEMBL4194557 0.89 BCL2L1 (0.43) PDE4BPDE4DFEN1KCNH2SCN5A
SCHEMBL4187658 0.89 POLB (0.47) PPARGPDE4BPDE4DTP53TRPV1
SCHEMBL4188348 0.87 CNR2 (0.43) PDE4BPDE4DTP53FEN1MAPT
SCHEMBL4183644 0.87 TP53 (0.43) PPARGPDE4BPDE4DTP53TRPV1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1925617-B1 HETEROCYCLIC COMPOUND, AND PRODUCTION PROCESS AND USE THEREOF ASKA PHARM CO LTD (JP) 2012-11-14 EP disclosed
US-8193356-B2 Heterocycle compound, and production process and application thereof ASKA PHARMACEUTICAL CO., LTD. (JP) 2012-06-05 US disclosed
US-20090131467-A1 Heterocycle Compound, and Production Process and Application Thereof ASKA PHARMACEUTICAL CO., LTD. (JP) 2009-05-21 US disclosed
EP-1925617-A1 HETEROCYCLIC COMPOUND, AND PRODUCTION PROCESS AND USE THEREOF ASKA Pharmaceutical Co., Ltd. (JP) 2008-05-28 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090131467-A1 Heterocycle Compound, and Production Process and Application Thereof PDE3B, PDE4B, PDE7A PPARG 3577/4885PDE4B 2/4885PDE4D 7/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.